1,4-bis-(2-hydroxy-benzyl)-1,4,7-triazacyclononane derivatives and similar compounds as ligands in iron(III) complexes for use as MRI contrast agents
HK40119938BActive Publication Date: 2026-07-10BRACCO IMAGING SPA
0 Cites 0 Cited by
Patent Information
- Application Number
- HK62025108233
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-07-28
- Filing Date
- 2025-06-06
- Publication Date
- 2026-07-10
- Estimated Expiration
- 2043-07-27
AI Technical Summary
Technical Problem
Current MRI contrast agents based on Gd(III) complexes face issues with kidney retention, environmental impact, and unsatisfactory stability and relaxivity, while Fe(III) complexes lack a balanced profile of high relaxivity, kinetic inertness, and stability to reduction.
Method used
Development of novel 1,4-bis-(2-hydroxy-benzyl)-1,4,7-triazacyclononane derivatives that form Fe(III) complexes with high relaxivity, kinetic inertness, and stability to reduction, suitable for use as MRI contrast agents.
Benefits of technology
The Fe(III) complexes exhibit a balanced profile of high relaxivity, kinetic inertness, and stability to reduction, providing effective image contrast in MRI without the drawbacks of existing agents.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.